Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel A Canales

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Medicina Clinica|November 10, 2009
[Doxorubicin-induced cardiotoxicity: are there effective alternatives for prevention?]Miguel A Canales
Medicina Clinica|June 15, 2007
[Oral cobalamin therapy: a note of caution]Miguel A Canales, Raquel de Paz, Fernando Hernández Navarro
Medicina Clinica|July 13, 2006
[Megaloblastic anemia]Raquel de Paz, Miguel A Canales, Fernando Hernández-Navarro
British Journal of Haematology|August 8, 2006
Treatment options in relapsed or refractory Hodgkin disease patients: the mini-BEAM regimen does exist tooMiguel A Canales, Alejandro Martin, Dolores Caballero, et al.
Leukemia Research|September 18, 2007
Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximabMonica Martin-Salces, Miguel A Canales, Raquel de Paz, et al.
American Journal of Hematology|June 6, 2008
Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?Maria J Garcia-Rodriguez, Miguel A Canales, Dolores Hernandez-Maraver, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|May 13, 2008
Nutritional recommendations in hematopoietic stem cell transplantationMonica Martin-Salces, Raquel de Paz, Miguel A Canales, et al.
Journal of Hematotherapy & Stem Cell Research|August 31, 2002
Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donorsMiguel A Canales, Rosario Arrieta, Ruben Gomez-Rioja, et al.
Cancer|August 13, 2009
Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue typeAntonio Salar, Eva Domingo-Domenech, Cristina Estany, et al.
Hemasphere|April 3, 2023
Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction AnalysisMiguel A Canales, Thomas A Buchholz, Jaisson A P Bortolini, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Medicina Clinica|November 10, 2009
[Doxorubicin-induced cardiotoxicity: are there effective alternatives for prevention?]Miguel A Canales
Medicina Clinica|June 15, 2007
[Oral cobalamin therapy: a note of caution]Miguel A Canales, Raquel de Paz, Fernando Hernández Navarro
Medicina Clinica|July 13, 2006
[Megaloblastic anemia]Raquel de Paz, Miguel A Canales, Fernando Hernández-Navarro
British Journal of Haematology|August 8, 2006
Treatment options in relapsed or refractory Hodgkin disease patients: the mini-BEAM regimen does exist tooMiguel A Canales, Alejandro Martin, Dolores Caballero, et al.
Leukemia Research|September 18, 2007
Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximabMonica Martin-Salces, Miguel A Canales, Raquel de Paz, et al.
American Journal of Hematology|June 6, 2008
Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?Maria J Garcia-Rodriguez, Miguel A Canales, Dolores Hernandez-Maraver, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|May 13, 2008
Nutritional recommendations in hematopoietic stem cell transplantationMonica Martin-Salces, Raquel de Paz, Miguel A Canales, et al.
Journal of Hematotherapy & Stem Cell Research|August 31, 2002
Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donorsMiguel A Canales, Rosario Arrieta, Ruben Gomez-Rioja, et al.
Cancer|August 13, 2009
Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue typeAntonio Salar, Eva Domingo-Domenech, Cristina Estany, et al.
Hemasphere|April 3, 2023
Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction AnalysisMiguel A Canales, Thomas A Buchholz, Jaisson A P Bortolini, et al.
Pageof 2